Cureus

Stellate ganglion block may help manage long COVID symptoms.

Updated

Abstract

Fifty-two patients with post-acute sequelae of SARS-CoV-2 reported symptom improvements after stellate ganglion block treatment.

  • Patients received an average of three stellate ganglion block injections.
  • Most patients experienced improvements in symptoms like brain fog, fatigue, dizziness, and headache.
  • About a quarter of patients reported at least one short-lived adverse effect.
  • The duration of symptom improvement varied significantly among patients.
  • Further randomized clinical trials may be needed to confirm the effectiveness of stellate ganglion blocks for PASC.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Mass General Brigham Institutional Review Board (IRB) issued approval (2023P003108). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free